Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab versus adalimumab monotherapy in active rheumatoid arthritis
2013-001417-32Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sirukumab in rheumatoid arthritis (RA) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in DAS28 (ESR). Started Feb 2014; status: completed.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-001417-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001417-32.